An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Phase 1

Completed

• Conditions: Bacterial Infections; Immunotherapy, Active; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcal Vaccines
• Interventions: Biological: SA3Ag vaccine; Biological: SA3Ag followed by Placebo; Biological: Placebo; Biological: SA3Ag with no booster in stage 2; Procedure: Placebo with no booster in stage 2; Procedure: Blood draw; Procedure: Colonization swab samples

• Registration Number: NCT01018641
• Lead Sponsor: Pfizer

Brief Summary

This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag). This study is primarily designed to assess how safe and well tolerated SA3Ag is, but will also describe the immune response over 12 months elicited by SA3Ag. Additionally, this study will assess the effect of SA3Ag vaccine on the number of Staphylococcus aureus bacteria that naturally occur on the skin and within the nose and throat.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-11-20
• Study First Submitted QC: 2009-11-20
• Study First Posted: 2009-11-23
• Study Start: 2010-01
• Primary Completion: 2011-01
• Study Completion: 2011-07
• Status Verified: 2014-04
• Last Update Submitted: 2014-04-23
• Last Update Posted: 2014-04-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 449

Inclusion Criteria

• Healthy adults aged 18 to 24 years or 50 to 85 years who are available for the entire duration of the study, able to be contacted by phone, and able to complete all study procedures, including completion of an electronic diary (e-diary).
• Men and women who are able to have children, must use a reliable method of birth control for the duration of the study.

Exclusion Criteria

• Any major illness that would substantially increase the risk associated with participation in the study, or interfere with the evaluation of the study objectives - this is determined by the local physician.
• Donation of 250 mL or more of blood within the last 3 months.
• Condition associated with prolonged bleeding time, including subjects taking anticoagulant medication or antiplatelet therapy.
• Any contraindication to vaccination or vaccine components.
• Immunocompromised persons and subjects who receive treatment with immunosuppressive therapy.
• Previous administration of S. aureus vaccination.
• Receipt of blood products or immunoglobulins within 12 months prior to study
• Participation in another trial (not including observational trials) within the last 30 days.
• Study site personnel or immediate family members (first-degree relatives).
• Women who are pregnant (as determined by urine pregnancy test) or breast-feeding.
• Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care.
• For subjects aged 65 years or older, a Mini-Mental State Examination (MMSE) score of <=21.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
5	Colonization swab samples	Placebo in stage 1 and no vaccine in stage 2.
1	SA3Ag vaccine	SA3Ag in both stage 1 and stage 2
1	Blood draw	SA3Ag in both stage 1 and stage 2
1	Colonization swab samples	SA3Ag in both stage 1 and stage 2
2	SA3Ag followed by Placebo	SA3Ag in stage 1 followed by placebo in stage 2.
2	Blood draw	SA3Ag in stage 1 followed by placebo in stage 2.
2	Colonization swab samples	SA3Ag in stage 1 followed by placebo in stage 2.
3	Placebo	Placebo in both stage 1 and stage 2
3	Blood draw	Placebo in both stage 1 and stage 2
3	Colonization swab samples	Placebo in both stage 1 and stage 2
4	SA3Ag with no booster in stage 2	SA3Ag in stage 1 and no vaccine in stage 2.
4	Blood draw	SA3Ag in stage 1 and no vaccine in stage 2.
4	Colonization swab samples	SA3Ag in stage 1 and no vaccine in stage 2.
5	Placebo with no booster in stage 2	Placebo in stage 1 and no vaccine in stage 2.
5	Blood draw	Placebo in stage 1 and no vaccine in stage 2.

Primary Outcome Measures

Name	Time	Method
The primary immunogenicity endpoint in stage 1 is antigen-specific antibody levels using an Ig binding assay (Ig titers) 28 days after vaccination at visit 1 in the 50- to 85-year age stratum at each vaccine group (3 SA3Ag dose levels and placebo).	1 month
The primary comparison of interest is a 2-fold increase in Ig titers relative to baseline for each antigen.	1 month

Secondary Outcome Measures

Name	Time	Method
The safety endpoints are solicited and unsolicited AEs, SAEs, and hematologic and urine parameters.	12 months
OPA titers for each antigen 28 days after vaccination in both age strata at selected dose level cohort(s).	1 month
The secondary immunogenicity endpoints are Ig titers for each antigen (CP5, CP8, and rClfAm) 28 days after vaccination in the 18- to 24-year age stratum at each dose level cohort.	1 month
Ig titers for each antigen 28 days after the booster dose.	7 months

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇦🇺 Subiaco, Western Australia, Australia